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Background: The available data on diagnostics and treatment of ischemic stroke (IS) in
Poland come mainly from non-representative cohorts or are outdated.
Objective: Therefore, the current study was done to access the most recent data on IS in the
industrial region that covers 12% of the country's population.
Materials & methods: Analysis of the data from stroke questionnaires, obligatory for all
patients hospitalized due to acute stroke and administered by the National Health Fund
(the only public health insurer in Poland) between 2009 and 2015 (n = 81,193).
Results: The number of hospitalizations due to IS in the Silesian Province was 69,403 and
constituted 85.5% of all stroke cases reported to the NHF between 2009 and 2015. Neuroim-
aging of the brain (CT/MRI) was performed in 68,696 (99%) subjects, while ultrasonography of
extra- and/or intracranial arteries in 57,886 (83.4%). The rtPA therapy was applied in 3282
patients (4.7% of all IS subjects). The rate of patients treated with rtPA gradually increased
(1.2% in 2009, 9.3% in 2015). Among all patients with IS, 57,636 (83.1%) subjects were
administered antiplatelet drugs, 16,199 (23.3%) – oral anticoagulants, and 55,971 (80.7%) –
antihypertensive drugs. Also, 2260 (3.3%) patients were referred for vascular intervention. In
subjects with cardioembolic stroke etiology, 37.8% were treated with anticoagulants.
Conclusions: There has been observed a signiﬁcant improvement in the quality of diagnosis
and treatment of acute ischemic stroke during recent years. However, further actions are
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902 Bytom, Poland.
E-mail address: broszak@sum.edu.pl (B. Łabuz-Roszak).
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnnshttps://doi.org/10.1016/j.pjnns.2017.11.003
0028-3843/© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
required both in terms of reperfusion treatment (thrombolysis and/or thrombectomy) and
secondary prevention of stroke.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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Stroke constitutes the third cause of death and the main cause
of permanent disability in adults in Europe. Due to poor
prognosis, high costs of treatment and chronic care, stroke is
not only a medical problem, but also a social issue.
Based on the studies conducted in various countries it was
documented that immediate hospitalization and treatment of
patients according to an approved standard in specialized
stroke units contributes to decreased mortality and lower
treatment costs. In Poland, including the Silesian Province,
there is a comprehensive network of stroke units and most
patients diagnosed with stroke are treated in such specialized
facilities [1,2].
Patients with ischemic stroke (IS) have had access to causal
treatment for several years. It consists in administering a
single dose of intravenous medication (alteplase – a recombi-
nant tissue plasminogen activator – rtPA) which dissolves
blood clots in an occluded cerebral artery [3–5]. The treatment
is known as intravenous thrombolytic therapy. In 1996 the use
of rtPA in AS was approved by the FDA, in 2002 this therapy
was registered by the European Commission, in 2003 it was
registered in Poland and since 2009 it has been fully
reimbursed to all patients by the NHF, which is the only
public health insurer in Poland.
There exist some reports concerning data on treatment of
stroke in certain hospitals, cities, districts and provinces of
Poland [6–8]. However, there is no comprehensive analysis
concerning diagnostics and treatment of IS in the Silesian
Province which is the second largest province in Poland with
approximately 4,600,000 citizens (nearly 12% of Poland's
population).
Therefore, the aim of this study was to analyze the use of
diagnostic methods (neuroimaging, ultrasonography) and
treatment of acute IS, as well as secondary stroke prevention
in the Silesian Province between 2009 and 2015.
2. Patients and methods
The study was based on the data obtained from stroke
questionnaires (n = 88,425) which were mandatorily reported
to the NHF by all Silesian hospital departments for stroke
patients (homogeneous patient groups: A48–A51). The ana-
lyzed period was between 2009 and 2015. The study was done
with the approval of the Silesian division of the NHF and the
Consultant in Neurology for the Silesian Province.
The questionnaire data were veriﬁed for incomplete or
recurring data (e.g. recurring records of the same hospitaliza-
tion were excluded). Finally, 81,193 stroke questionnaires wereenrolled for the analysis. Diagnosis of stroke was made
according to the International Classiﬁcation of Diseases
version 10 (ICD-10).
The following data from the stroke questionnaires were
used in the present study: age, sex, admission date, date of
the ﬁrst occurrence of stroke symptoms, date of death or
discharge, number of hospitalization days, etiology of IS
(according to the Trial Org 10172 in Acute Stroke Treatment –
TOAST), clinical symptoms (consciousness disorders,
hemiparesis/hemiplegia, speech disorders, sensory disorders,
posterior circle syndrome), secondary stroke prevention
(antiplatelets, anticoagulants, antihypertensives), information
on referral for vascular intervention due to artery stenosis,
application of rtPA, use of neuroimaging (CT/MRI) and
ultrasonography of intra- and extracerebral arteries.
According to the Bioethics Committee, the study was not a
medical experiment. Therefore, no approval of the Committee
was required.
The statistical analysis was done using the statistical
package SAS version 9.4 (SAS Institute Inc., Cary, NC). The level
of statistical signiﬁcance was set at P < 0.05.
The quantitative data were characterized using the mean
and the standard deviation. For nominal data the percentage
values were used. The correlation between the nominal
variables was veriﬁed using the x2 test. The veriﬁcation of
the distribution of the variables and the agreement with the
normal distribution were made using the Shapiro–Wilk test.
The mean difference signiﬁcance was veriﬁed using the
Student's t-test for two groups and the ANOVA test for three
or more groups. The consistency of the distribution was
veriﬁed using the Mann–Whitney U test for groups and the
Kruskal–Wallis test for skewed distributions. Multiple com-
parisons were made based on post hoc test results for variance
analysis (ANOVA) and the Kruskal–Wallis test with the
Bonferroni correction to assess signiﬁcance of the percentage
difference in the case of two or more groups. The test for trend
was also calculated for consecutive years by means of
Jonckheere–Terpstra and Cochran–Armitage tests for contin-
uous and categorical variables, respectively.
3. Results
Based on the analysis of data obtained from the stroke
questionnaires it was shown that the number of hospitaliza-
tions due to IS in the Silesian Province between 2009 and 2015
was 69,403 (35,880 women and 33,107 men; P < 0.001) which
constituted 85.5% of all stroke cases reported to the NHF
(n = 81,193). In 416 cases the data on sex were not available.
The mean age of subjects hospitalized due to IS was 72.2  11.8
years (F – 75.4  11.5 years, M – 68.8  11.2 years; P < 0.05). The
Table 1 – Percentage of hospitalizations due to ischemic
stroke (I63) with performed diagnostic procedures (Brain
CT/MRI and USG of extra- and/or intracranial arteries) in
the Silesian Province between 2009 and 2015.
Year Number of all
hospitalizations
due to ischemic
stroke (I63)
N
Brain
CT/MRI [%]
USG of
extra- and/or
intracerebral
arteries [%]
2009 9275 98.9 65.2
2010 10,058 98.7 81.6
2011 10,223 98.6 84.2
2012 10,187 99.2 86.1
2013 10,289 99.1 87.6
2014 9850 99.1 88.7
2015 9521 99.3 89.3
Pa – <0.001 <0.001
All 69,403 99 83.4
a Trend test Cochran–Armitage.
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hospitalization was 0.74  3.4 days, and it was stable over
years.
Neuroimaging of the brain (CT/MRI) was performed in
68,696 (99.1%), and ultrasonography of extra- and/or intracra-
nial arteries – in 57,886 (83.4%) of patients. The frequency of
use of diagnostic methods in subjects with IS is shown in
Table 1.
The rtPA therapy was applied to 3282 patients with IS (I63)
treated in hospitals of the Silesian Province between 2009 and
2015. It constituted 4.7% of all cases of I63-diagnosed
hospitalizations. The number of patients who received
thrombolytic therapy was increasing gradually in the subse-
quent years (Fig. 1).
The mean hospitalization time in patients with IS treated
with rtPA was 14.4  11.7 days. It was statistically signiﬁcantly
longer than in patients with IS not receiving intravenous
thrombolytic therapy (13.6  10.8 days; P = 0.01). Table 2Fig. 1 – Intravenous thrombolytic therapy (rt-PA) in patients with
Province between 2009 and 2015. Data presented as N (%) (Trendpresents the length of in-hospital stay for patients with IS
treated and untreated with rtPA in the consecutive years.
The overall number of male and female patients treated
with rtPA was 1690 (51.9%) and 1565 (48.1%), respectively (for 27
patients data concerning sex were not available) (P < 0.001).
Table 3 shows sex distribution of patients treated with rtPA in
the consecutive years.
The mean age of all patients who received rtPA therapy in
the analyzed period was statistically signiﬁcantly lower (70.2
 12.4 years) when compared to the mean age of patients
untreated with rtPA (72.3  11.8 years; P < 0.001). The mean
age of patients treated with rtPA was gradually increasing in
the subsequent years (P < 0.001) (Fig. 2).
The overall in-hospital mortality in patients treated with
rtPA (number of deaths = 514; 15.7%) was not statistically
signiﬁcantly higher when compared to the in-hospital
mortality of patients untreated with rtPA (number of
deaths = 9825; 14.9%) (P = 0.210). Fig. 3 shows the in-hospital
mortality for patients treated and untreated with rtPA in the
consecutive years.
The in-hospital mortality in patients treated with rtPA was
similar in men (15.6%) and women (15.8%) (P = 0.899).
The etiology of IS in patients who received intravenous
trombolysis and the in-hospital mortality depending on stroke
etiology is presented in Table 4.
Data obtained from the stroke questionnaires allowed to
determine the secondary stroke preventive therapy applied in
patients with IS (I63); 57,636 (83.1%) subjects were adminis-
tered antiplatelet drugs, 16,199 (23.3%) – oral anticoagulants,
and 55,971 (80.7%) – antihypertensive drugs. Furthermore, 2260
(3.3%) patients were referred for vascular intervention due to
artery stenosis. Table 5 shows the application of secondary
stroke prevention in the consecutive years.
In patients with cardioembolic stroke etiology (n = 12,973),
4902 (37.8%) subjects were administered anticoagulants. The
percentage of patients with cardioembolic stroke treated with
anticoagulants were gradually increasing in the subsequent
years (P = 0.014) while the negative trend was observed for
antiplatelet drugs (Fig. 4). ischemic stroke (I63) treated in hospitals of the Silesian
 test Cochran–Armitage; P < 0.001).
Table 2 – Hospitalization time of patients with ischemic
stroke (I63) treated and untreated with intravenous
thrombolytic therapy (rtPA) in the Silesian Province
between 2009 and 2015. Data presented as mean W SD in
days.
Year Hospitalization
time in treated
with rt-PA [days]
Hospitalization
time in untreated
with rt-PA [days]
Pa
2009 13.9  8.1 14.0  10.1 0.878
2010 14.9  11.1 13.9  10.4 0.236
2011 16.6  17.1 13.9  11.9 <0001
2012 14.4  11.7 13.6  13.4 0.141
2013 14.4  11.2 13.2  9.7 0.016
2014 14.2  11.2 13.6  10.2 0.181
2015 13.7  10.7 13.1  9.1 0.090
Pb 0.001 <0.001 –
All 14.4  11.7 13.6  10.8 <0.001
a ANOVA post hoc tests.
b Trend test Jonckheere–Terpstra.
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The stroke incidence rate in the Silesian Province is very high –
it varied from 169/100,000 to 187/100,000 per year (data from
the paper of authors in press). It constitutes a major diagnostic
and therapeutic issue. Most strokes are ischemic (85.5%) with
atherosclerotic etiology, thus primary prevention of athero-
sclerosis is of great importance.
The rtPA therapy signiﬁcantly increases the chance of
minimal or no disability (by approximately 30%) at three
months after stroke onset [3]. In the Silesian Province the
number of patients treated with rtPA gradually increased since
intravenous thrombolysis was reimbursed by the NHF in
Poland. In 2009 only 1.2% of patients with IS were treated with
intravenous thrombolytic therapy. However, in 2015 this
percentage reached 9.3% of all subjects with IS. Generally, in
the analyzed period 4% of patients with IS were treated with
rtPA in the Silesian hospitals.
To compare, there are some data from rare recent studies
conducted in other Polish regions: the percentage of patients
treated with rtPA in the Swietokrzyskie Province was 8.8%
(2009) whereas in the Pomeranian Province – 2.9% (2009) [7]. It
should be stressed that the number of patients analyzed in
these studies was much lower and the analyzed period
signiﬁcantly shorter than in the present study.
In some Western European countries the percentage of
patients with IS treated with rtPA was higher than in the
Silesian Province. For instance, the use of thrombolysis in
England, Wales and Northern Ireland increased from 1.8%
in 2008 to 12.2% in 2014 [9] and in Dutch hospitals from 6.4% in
2005 to 14.6% in 2012 [10]. There are also regions where
thrombolysis rates are much higher, e.g. 15.7% in South
London and, up to 35% in the German state of Hesse
(2007–2008) [11,12]. However, in other regions the situation
seemed to be similar, e.g. in Scotland it increased from 3% to
9% from 2008 to 2013 [13].
In the United States, where rtPA has been used since 1996 (6
years earlier than in Europe), the percentage of thrombolyzed
patients reached 20–30% in some hospitals and quality
Fig. 2 – Mean age of patients with ischemic stroke (I63) treated with intravenous thrombolytic therapy (rt-PA) in hospitals of
the Silesian Province between 2009 and 2015. Data presented as mean W SD (Trend test Jonckheere-Terpstra; P < 0.001).
Fig. 3 – In-hospital mortality in patients treated with intravenous thrombolytic therapy (rt-PA) compared to in-hospital
mortality of patients untreated with rt-PA in the Silesian Province between 2009 and 2015 (test chi2 with the Bonferroni
correction – significance level set at 0.007: 2009: P = 0.031; 2010: P = 0.771; 2011: P = 0.485; 2012: P = 0.799; 2013: P = 0.395;
2014: P = 0.048; 2015: P = 0.104).
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3% to 5% in the last decade [14–18]. It should be stressed that
also in some Silesian hospitals (mostly university) the
percentage of rtPA treated patients has reached almost 20%
in the recent years [6]. However, there are still neurological
departments in the Silesian Province where intravenous
thrombolysis is very rarely used.
The main factor that limits the availability of thrombolytic
therapy, not only in the Silesian Province, is a short period of
time (small time windows) when the drug can be administered
– 4.5 h (initially 3 h) from the occurrence of stroke symptoms
[3–5]. The social awareness of stroke symptoms and available
treatment options is still insufﬁcient, and as a result
many patients are admitted to hospital when it is already
too late [19].
We found that the in-hospital mortality in patients treated
and untreated with rtPA was similar, which is consistent with
other reports [18]. The results from the SITS-ISTR and VISTAcombined (n = 29,500) revealed a reduction of death in patients
receiving alteplase in a prospective observation which lasted
longer (3 months) compared to our study. [18]
In our study the percentage of men treated with rtPA was
higher than the similar percentage of women, which is
consistent with other studies [20]. But the in-hospital mortality
was similar both in thrombolyzed women and men. However,
some other researchers reported that women achieved better
results after intravenous thrombolysis [20]. In our study we
were not able to establish the functional status but some
authors reported that a 3-month functional outcome was
signiﬁcantly better in women compared to men [21–23].
Contrary to the above studies, other authors described a
reverse situation – the outcome in women after rtPA was
worse than in men [24].
Our study revealed that the in-hospital mortality in
patients with cardioembolic etiology of IS was lower in
subjects treated with rtPA (16.9%) than in those untreated
Table 4 – In-hospital mortality in patients with ischemic stroke (I63) treated (N = 3282) and untreated (N = 66,121) with rtPA
according to the etiology of stroke. Data presented as N (%).
Etiology of
ischemic stroke
(TOAST)
Patients treated
with rtPA
In-hospital mortality
in patients treated
with rtPA
Patients untreated
with rtPA
In-hospital mortality
in patients untreated
with rtPA
Pa
In-hospital
mortality in treated
vs untreated
with rtPA
Large-artery
atherosclerosis
1127 (34.4%) 178 (15.8%) 23,927 (36.2%) 3421 (14.3%) 0.161
Cardioembolism 884 (26.9%) 149 (16.9%) 12,089 (18.3%) 2351 (19.5%) 0.050
Small artery
occlusion (lacunar)
234 (7.1%) 21 (8.9%) 6512 (9.9%) 345 (5.3%) 0.015
Other determined
etiology
45 (1.4%) 4 (8.9%) 1220 (1.8%) 145 (11.9%) 0.540
Undetermined
etiology
992 (30.2%) 162 (16.3%) 22,373 (33.8%) 3563 (15.9%) 0.733
Total 3282 (100%) 514 (15.7%) 66,121 (100%) 9825 (14.9%) 0.210
a Chi2 test.
Table 5 – Secondary stroke prevention in patients with ischemic stroke (I63) in the Silesian Province between 2009 and
2015. Data presented as N (%).
Year Oral antiplatelet
drugs
Oral anticoagulant
drugs
Antihypertensive
drugs
Direction for vascular intervention
due to artery stenosisb
2009 7303 (78.7%) 2194 (23.6%) 7095 (76.5%) 202 (2.1%)
2010 8383 (83.3%) 2650 (26.3%) 7939 (78.9%) 350 (3.4%)
2011 8535 (83.4%) 2608 (25.5%) 8233 (80.5%) 315 (3.0%)
2012 8655 (84.9%) 2593 (25.4%) 8193 (80.4%) 379 (3.7%)
2013 8682 (84.3%) 2301 (22.3%) 8331 (80.9%) 344 (3.3%)
2014 8248 (83.7%) 1965 (19.9%) 8187 (83.1%) 344 (3.3%)
2015 7830 (82.2%) 1888 (19.8%) 7993 (83.9%) 326 (3.4%)
All 57,636 (83.0%) 16,199 (23.3%) 55,971 (80.6%) 2260 (3.2%)
Pa <0.001 <0.001 <0.001 <0.001
a Trend test Cochran–Armitage.
b Endarterectomy or angioplasty of cervical artery.
Fig. 4 – Secondary stroke prevention in patients with ischemic stroke (I63) of cardioembolic etiology. Data presented as
percentage of patients with ischemic stroke after discharge from hospital receiving the given drug (Trend test Cochran–
Armitage for antiplatelets P < 0.001; for oral anticoagulants P = 0.014).
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 2 3 5 – 2 4 2240(19.5%) (P = 0.05). Cardioembolic strokes are usually associated
with a more severe neurological impairment and higher
mortality [20,25]. However, ﬁbrin-rich and smaller volume
embolic clots, often observed in cardioembolism, might berelatively better for recanalization after intravenous throm-
bolysis and it might be the reason why patients with
cardioembolic etiology of IS beneﬁt more from the rtPA
treatment than patients with large artery atherosclerosis.
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patients with IS – regardless of its etiology (atherosclerosis or
cardioembolic) – had antiplatelet drugs prescribed as second-
ary stroke prevention (in 2009 – 78.7%; in 2015 – 82.2%).
However, the number of patients with cardioembolic stroke
receiving anticoagulants gradually increased over years (2009 –
37.6%, 2015 – 39.7%) with concomitant decrease in patients
treated with antiplatelets (2009 – 68.9%, 2015 – 62.5%).
The number of Silesian patients after IS receiving second-
ary pharmacological stroke prevention seemed to be high,
when compared to the results from previous Polish studies
(e.g. multicenter, population-based PolSenior study conducted
between 2008 and 2010). In the PolSenior study (n = 5696),
among 426 subjects with a history of a previous stroke, 261
people (61.3%) used at least one drug as a secondary
prevention; oral antiplatelets were regularly used by 237
people (55.6%), and oral anticoagulants – by 25 people (5.9%).
Also the number of PolSenior patients with IS and atrial
ﬁbrillation receiving oral anticoagulants was much lower than
in our study – 20% [26].
However, in other European countries many more patients
have been instructed on stroke prevention. In the PREFER in AF
registry (Prevention of Thromboembolic Events – European
Registry in Atrial Fibrillation) the authors collected data from
several European countries (Austria, France, Germany, Italy,
Spain, Switzerland, and the UK) [27]. They described that oral
anticoagulats were used by 82.3% of all subjects with atrial
ﬁbrillation and by 84% of patients with at least 1 point in
CHA2DS2VASc. Anticoagulants were the least frequently used
in Italy (71.%), whereas in France they were the most often
administered (90%) [27].
Other studies also showed similar trends [28,29]. GARFIELD-
AF registry (an ongoing prospective, multicenter, international
registry of patients newly diagnosed AF) demonstrated that
preventive therapy with oral anticoagulants was generally
higher in other European countries (41.9%–55.5%) than in
Poland (36.9%–41.7%).
Our study may help in the implementation of proper health
education initiatives in the Silesian Province, thus contribut-
ing to better health of the society. People should be instructed
how to detect symptoms of stroke and call for help in a timely
manner, as the rate of patients treated with intravenous
thrombolysis is still relatively low despite the continuous
increase.
5. Conclusions
1. The frequency of application of diagnostic methods in
stroke (CT/MRI, USG) has still been increasing since 2009,
particularly in the case of ultrasound of extra- and or
intracranial arteries.
2. The rate of patients treated with rtPA in the Silesian
Province has been continuously growing since 2009 al-
though it is still too low. Statistically signiﬁcantly more men
were treated with rtPA than women.
3. The in-hospital mortality in patients receiving intravenous
thrombolytic therapy is similar to those who were not
treated with rtPA.4. As secondary stroke prevention, antiplatelet drugs were
used most often, also for strokes of cardioembolic etiology.
However, the number of patients receiving oral antic-
oagulants has still been growing.
6. Limitations of the study
There are a few limitations to this study. First, in our paper we
analyzed only stroke-related hospitalizations but in Poland
almost all patients with AS are admitted to hospitals. It is also
possible that in the case of some ASs the questionnaires might
not have been sent to the NHF. Third, we only analyzed the
questionnaire data and only information given in them. As a
result, some human errors could have been made.
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